124 related articles for article (PubMed ID: 32670103)
21. Exploratory Analysis of the Effects of Celecoxib on Cognitive Function in Vortioxetine-Treated Patients With Major Depressive Disorder in the PREDDICT Study: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Sampson E; Mills NT; Hori H; Schwarte K; Hohoff C; Schubert O; Clark SR; Fourrier C; Baune BT
J Clin Psychiatry; 2023 Oct; 84(6):. PubMed ID: 37796652
[No Abstract] [Full Text] [Related]
22. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders.
Christensen MC; Loft H; McIntyre RS
J Affect Disord; 2018 Feb; 227():787-794. PubMed ID: 29689693
[TBL] [Abstract][Full Text] [Related]
23. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults.
McIntyre RS; Lophaven S; Olsen CK
Int J Neuropsychopharmacol; 2014 Oct; 17(10):1557-67. PubMed ID: 24787143
[TBL] [Abstract][Full Text] [Related]
24. Validation of the University of California San Diego Performance-based Skills Assessment (UPSA) in major depressive disorder: Replication and extension of initial findings.
Christensen MC; Sluth LB; McIntyre RS
J Affect Disord; 2019 Feb; 245():508-516. PubMed ID: 30439678
[TBL] [Abstract][Full Text] [Related]
25. Which Cognitive Domains are Improved by Treatment with Vortioxetine?
Harrison JE; Lophaven S; Olsen CK
Int J Neuropsychopharmacol; 2016 May; 19(10):. PubMed ID: 27231256
[TBL] [Abstract][Full Text] [Related]
26. THINC-Integrated Tool (THINC-it): A Brief Measurement of Changes in Cognitive Functioning and Its Correlation with the Life Quality of Patients with Schizophrenia and Related Disorders-A Pilot Study.
Szmyd JK; Lewczuk K; Teopiz KM; McIntyre RS; Wichniak A
Brain Sci; 2023 Feb; 13(3):. PubMed ID: 36979199
[TBL] [Abstract][Full Text] [Related]
27. Prediction of residual cognitive disturbances by early response of depressive symptoms to antidepressant treatments in patients with major depressive disorder.
Sumiyoshi T; Hoshino T; Mishiro I; Hammer-Helmich L; Ge H; Moriguchi Y; Fujikawa K; Fernandez JL
J Affect Disord; 2022 Jan; 296():95-102. PubMed ID: 34597893
[TBL] [Abstract][Full Text] [Related]
28. Recognition and Treatment of Cognitive Dysfunction in Major Depressive Disorder.
Zuckerman H; Pan Z; Park C; Brietzke E; Musial N; Shariq AS; Iacobucci M; Yim SJ; Lui LMW; Rong C; McIntyre RS
Front Psychiatry; 2018; 9():655. PubMed ID: 30564155
[TBL] [Abstract][Full Text] [Related]
29. Vortioxetine for major depressive disorder, vasomotor, and cognitive symptoms associated with the menopausal transition.
Freeman MP; Cheng LJ; Moustafa D; Davies A; Sosinsky AZ; Wang B; Petrillo LF; Hogan C; Cohen LS
Ann Clin Psychiatry; 2017 Nov; 29(4):249-257. PubMed ID: 29069110
[TBL] [Abstract][Full Text] [Related]
30. A Network Meta-Analysis Comparing Effects of Various Antidepressant Classes on the Digit Symbol Substitution Test (DSST) as a Measure of Cognitive Dysfunction in Patients with Major Depressive Disorder.
Baune BT; Brignone M; Larsen KG
Int J Neuropsychopharmacol; 2018 Feb; 21(2):97-107. PubMed ID: 29053849
[TBL] [Abstract][Full Text] [Related]
31. Further validation of the THINC-it tool and extension of the normative data set in a study of n = 10.019 typical controls.
Dalby M; Annas P; ; Harrison JE
Int J Methods Psychiatr Res; 2022 Dec; 31(4):e1922. PubMed ID: 35748111
[TBL] [Abstract][Full Text] [Related]
32. Insulin resistance is associated with deficits in hedonic, self-reported cognitive, and psychosocial functional response to antidepressant treatment in individuals with major depressive disorder.
Rashidian H; Subramaniapillai M; Park C; Lipsitz O; Zuckerman H; Teopiz K; Cao B; Lee Y; Gill H; Ho R; Lin K; Rodrigues NB; Iacobucci M; Rosenblat JD; McIntyre RS; Mansur RB
J Affect Disord; 2021 Mar; 282():448-453. PubMed ID: 33422821
[TBL] [Abstract][Full Text] [Related]
33. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study.
Baune BT; Sluth LB; Olsen CK
J Affect Disord; 2018 Mar; 229():421-428. PubMed ID: 29331703
[TBL] [Abstract][Full Text] [Related]
34. Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study.
Mansur RB; Ahmed J; Cha DS; Woldeyohannes HO; Subramaniapillai M; Lovshin J; Lee JG; Lee JH; Brietzke E; Reininghaus EZ; Sim K; Vinberg M; Rasgon N; Hajek T; McIntyre RS
J Affect Disord; 2017 Jan; 207():114-120. PubMed ID: 27721184
[TBL] [Abstract][Full Text] [Related]
35. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
[TBL] [Abstract][Full Text] [Related]
36. Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset.
Iovieno N; Papakostas GI; Feeney A; Fava M; Mathew SJ; Iosifescu DI; Murrough JW; Macaluso M; Hock RS; Jha MK
J Clin Psychiatry; 2021 Jun; 82(4):. PubMed ID: 34133089
[No Abstract] [Full Text] [Related]
37. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder.
Mahableshwarkar AR; Zajecka J; Jacobson W; Chen Y; Keefe RS
Neuropsychopharmacology; 2015 Jul; 40(8):2025-37. PubMed ID: 25687662
[TBL] [Abstract][Full Text] [Related]
38. The effects of desvenlafaxine on neurocognitive and work functioning in employed outpatients with major depressive disorder.
Lam RW; Iverson GL; Evans VC; Yatham LN; Stewart K; Tam EM; Axler A; Woo C
J Affect Disord; 2016 Oct; 203():55-61. PubMed ID: 27280963
[TBL] [Abstract][Full Text] [Related]
39. Serum insulin-like growth factor-1 as a potential marker for MDD diagnosis, its clinical characteristics, and treatment efficacy validation: data from an open-label vortioxetine study.
Levada OA; Troyan AS; Pinchuk IY
BMC Psychiatry; 2020 May; 20(1):208. PubMed ID: 32384884
[TBL] [Abstract][Full Text] [Related]
40. Improved cognitive function in patients with major depressive disorder after treatment with vortioxetine: A EEG study.
Kim H; Baik SY; Kim YW; Lee SH
Neuropsychopharmacol Rep; 2022 Mar; 42(1):21-31. PubMed ID: 34894110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
